IL285315A - Imidazo[1,2-f][4,2,1]triazine-4-amine derivatives as tlr7 agonists - Google Patents

Imidazo[1,2-f][4,2,1]triazine-4-amine derivatives as tlr7 agonists

Info

Publication number
IL285315A
IL285315A IL285315A IL28531521A IL285315A IL 285315 A IL285315 A IL 285315A IL 285315 A IL285315 A IL 285315A IL 28531521 A IL28531521 A IL 28531521A IL 285315 A IL285315 A IL 285315A
Authority
IL
Israel
Prior art keywords
triazin
imidazo
amine derivatives
tlr7 agonist
tlr7
Prior art date
Application number
IL285315A
Other languages
English (en)
Hebrew (he)
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of IL285315A publication Critical patent/IL285315A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL285315A 2019-02-07 2021-08-02 Imidazo[1,2-f][4,2,1]triazine-4-amine derivatives as tlr7 agonists IL285315A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2019074732 2019-02-07
CN2019098757 2019-07-31
CN2020073673 2020-01-22
PCT/CN2020/074436 WO2020160710A1 (en) 2019-02-07 2020-02-06 Imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivatives as tlr7 agonist

Publications (1)

Publication Number Publication Date
IL285315A true IL285315A (en) 2021-09-30

Family

ID=71947004

Family Applications (2)

Application Number Title Priority Date Filing Date
IL285311A IL285311A (en) 2019-02-07 2021-08-02 Imidazo[1,2-f][4,2,1]triazine-4-amine derivatives as tlr7 agonists
IL285315A IL285315A (en) 2019-02-07 2021-08-02 Imidazo[1,2-f][4,2,1]triazine-4-amine derivatives as tlr7 agonists

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL285311A IL285311A (en) 2019-02-07 2021-08-02 Imidazo[1,2-f][4,2,1]triazine-4-amine derivatives as tlr7 agonists

Country Status (14)

Country Link
US (2) US20230167117A1 (zh)
EP (2) EP3921320B1 (zh)
JP (2) JP2022519374A (zh)
KR (2) KR20210125025A (zh)
CN (2) CN113454086A (zh)
AU (2) AU2020218383A1 (zh)
BR (2) BR112021015016A2 (zh)
CA (2) CA3129234A1 (zh)
IL (2) IL285311A (zh)
MX (2) MX2021009439A (zh)
SG (2) SG11202108283QA (zh)
TW (2) TWI835999B (zh)
WO (2) WO2020160711A1 (zh)
ZA (2) ZA202105338B (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3788050B1 (en) 2018-05-01 2024-08-28 Revolution Medicines, Inc. C26-linked rapamycin analogs as mtor inhibitors
IL300091A (en) 2018-05-01 2023-03-01 Revolution Medicines Inc C40-, C28-, and C-32-linked rapamycin analogs as MTOR inhibitors
CN113454086A (zh) 2019-02-07 2021-09-28 百济神州有限公司 作为tlr7激动剂的咪唑并[2,1-f][1,2,4]三嗪-4-胺衍生物
CN112321590A (zh) * 2019-08-02 2021-02-05 百济神州有限公司 咪唑并[2,1-f][1,2,4]三嗪-4-胺衍生物作为tlr8激动剂
AR122159A1 (es) * 2020-05-28 2022-08-17 Novartis Ag Inhibidores de mll1 y agentes antineoplásicos
CN114057746A (zh) * 2020-08-04 2022-02-18 百济神州(北京)生物科技有限公司 作为tlr7激动剂的咪唑并[2,1-f][1,2,4]三嗪-4-胺衍生物的制备
CN114805392A (zh) * 2021-01-20 2022-07-29 上海维申医药有限公司 大环tlr7激动剂、其制备方法、药物组合物及其用途
TW202304863A (zh) * 2021-04-09 2023-02-01 美商銳新醫藥公司 雷帕黴素類似物化合物之合成
WO2023002011A1 (en) * 2021-07-23 2023-01-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Gram-negative bacteria efflux pump inhibitors
WO2023172347A1 (en) * 2022-03-10 2023-09-14 Nammi Therapeutics, Inc. Formulated and/or co-formulated lipid nanocarriers compositions containing toll-like receptor ("tlr") agonist prodrugs useful in the treatment of cancer and methods thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210891A1 (en) * 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
SG173617A1 (en) * 2009-02-11 2011-09-29 Univ California Toll-like receptor modulators and treatment of diseases
EP2480552B1 (en) * 2009-09-21 2016-11-09 Gilead Sciences, Inc. 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
JO3407B1 (ar) * 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
WO2014035140A2 (en) * 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
CN105367576A (zh) * 2014-08-15 2016-03-02 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
EA032824B1 (ru) 2014-08-15 2019-07-31 Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
WO2016097347A1 (en) 2014-12-19 2016-06-23 Janssen Pharmaceutica Nv IMIDAZOPYRIDAZINE DERIVATIVES AS ΡΙ3Κβ INHIBITORS
AU2016261730A1 (en) 2015-05-12 2017-11-16 Zeno Royalties & Milestones, LLC Bicyclic compounds
TW201803871A (zh) * 2016-06-24 2018-02-01 英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物
US11084818B2 (en) 2016-11-11 2021-08-10 Hepo Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compound, preparation method, intermediate, pharmaceutical composition and use
EP3636646A4 (en) * 2017-05-18 2020-12-09 Jiangsu Hengrui Medicine Co., Ltd. HETEROARYL PYRAZOL DERIVATIVE AND MANUFACTURING METHOD FOR IT AND MEDICAL USES THEREOF
CN113454086A (zh) 2019-02-07 2021-09-28 百济神州有限公司 作为tlr7激动剂的咪唑并[2,1-f][1,2,4]三嗪-4-胺衍生物

Also Published As

Publication number Publication date
TWI835999B (zh) 2024-03-21
EP3921319A1 (en) 2021-12-15
EP3921320A4 (en) 2022-11-09
EP3921320B1 (en) 2024-03-06
TWI841679B (zh) 2024-05-11
WO2020160711A1 (en) 2020-08-13
AU2020218872A1 (en) 2021-08-26
IL285311A (en) 2021-09-30
US20220119394A1 (en) 2022-04-21
BR112021015012A2 (pt) 2021-10-05
MX2021009439A (es) 2021-11-12
CA3129234A1 (en) 2020-08-13
EP3921319B1 (en) 2024-03-06
BR112021015016A2 (pt) 2021-10-05
MX2021009444A (es) 2021-11-12
CN113423708A (zh) 2021-09-21
SG11202108283QA (en) 2021-08-30
JP2022519374A (ja) 2022-03-23
ZA202105339B (en) 2023-02-22
TW202045507A (zh) 2020-12-16
KR20210125026A (ko) 2021-10-15
JP7564112B2 (ja) 2024-10-08
EP3921319C0 (en) 2024-03-06
EP3921320A1 (en) 2021-12-15
KR20210125025A (ko) 2021-10-15
US20230167117A1 (en) 2023-06-01
EP3921320C0 (en) 2024-03-06
WO2020160710A1 (en) 2020-08-13
JP2022521473A (ja) 2022-04-08
AU2020218383A1 (en) 2021-09-02
CN113454086A (zh) 2021-09-28
CA3129178A1 (en) 2020-08-13
ZA202105338B (en) 2022-08-31
EP3921319A4 (en) 2022-11-23
SG11202108284TA (en) 2021-08-30
TW202045508A (zh) 2020-12-16

Similar Documents

Publication Publication Date Title
IL285315A (en) Imidazo[1,2-f][4,2,1]triazine-4-amine derivatives as tlr7 agonists
HK1258157A1 (zh) 作為jak抑制劑的吡唑並[1，5-a]吡嗪-4-基衍生物
EP4008720A4 (en) IMIDAZO [2,1-F][1,2,4] TRIAZINE-4-AMINE DERIVATIVES AS A TLR8 AGONIST
IL290445A (en) [4,2,1]triazolo[5,1-c]quinazoline-5-amines
IL290419A (en) Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta
IL272988A (en) Imidazo-[1,5-A]pyrazine derivatives as PI3K-delta inhibitors
HUE056561T2 (hu) Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok
IL279654A (en) Pyrrolo[1,2-B]pyridazine derivatives
IL280122A (en) Imidazo[2,1-B]pyridazine derivatives as TRK inhibitors
SG11202108648TA (en) 7h-pyrrolo[2,3-d]pyrimidine-4-amine derivative
IL279156A (en) History of hexahydropyrrolo[4,3-C]pyrrole useful as LOX inhibitors